- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Gilead Faces Patent Challenge in France Over Sofosbuvir
The organization challenging Gilead is Médecins du Monde (MdM), an NGO that provides healthcare for vulnerable people around the world.
Doctors in France are challenging the patent of a new and highly expensive drug for hepatitis C in an attempt to bring down the price.
Sofosbuvir, costs $1,000 (£650) a pill for a 10-week course. The drug, made by the pharmaceutical multinational Gilead Sciences, is a cure for the viral infection that can lead to liver cirrhosis, cancer and death.
Even for affluent countries the bill is huge. In England, approximately 160,000 people are infected while globally, between 130 million and 150 million people are estimated to be infected, according to the World Health Organisation.
Read the complete news on The Guardian: http://bit.ly/1EVGZ7K
HIV, Hepatitis C Testing Rates Remain Dismal Among Injection Drug Users
April 17th 2020Despite being at an increased risk for HIV and hepatitis C, persons who inject drugs (PWID) are tested at dismal rates for both: just 8.6% and 7.7%, respectively, according to data from 2010 to 2017. PWID who live in rural communities are more likely to face barriers to adequate testing and care for both diseases.
Read More
Dr Rebekah Gee Offers an Inside Look at Louisiana's Subscription Payment Model for HCV Drugs
May 7th 2019We speak with Dr Rebekah Gee, secretary of the Louisiana Department of Health about the subscription payment model for hepatitis C virus drugs that the state has entered into with Asegua Therapeutics, a subsidiary of Gilead Sciences.
Listen
